Management of HBsAg Reactive Patients

Initial Diagnostic Workup

The American Association for the Study of Liver Diseases recommends measuring HBV DNA by PCR to quantify viral replication status, which is the single most critical test for distinguishing active disease from inactive carrier state 1, 2
The European Association for the Study of the Liver suggests checking HBeAg and anti-HBe status to classify the infection phase (HBeAg-positive vs HBeAg-negative chronic hepatitis B) 1, 2
Obtaining liver enzymes (ALT/AST) is essential as elevated transaminases indicate hepatic inflammation requiring treatment consideration 1, 2
Screening for coinfections: anti-HCV, anti-HDV (if injection drug use history), and anti-HIV is crucial as these alter management and prognosis 2, 3

The American Association for the Study of Liver Diseases recommends initiating antiviral therapy immediately if HBV DNA ≥20,000 IU/mL AND ALT >2× upper limit of normal (ULN) 2
Consider treatment for patients over age 30 with persistently normal ALT and high HBV DNA as prolonged immune tolerance increases cirrhosis and HCC risk 2
First-line agents: entecavir 0.5 mg daily OR tenofovir (disoproxil fumarate or alafenamide) due to high barrier to resistance 1, 2

All HBsAg-positive patients receiving chemotherapy or immunosuppressive therapy require prophylactic antiviral therapy, regardless of HBV DNA levels 4, 2
Start antiviral prophylaxis 2-4 weeks before initiating immunosuppression to prevent HBV reactivation, which occurs in 12-50% of untreated patients receiving high-risk agents like rituximab 2
Continue prophylaxis through treatment and for 12 months after cessation (24 months for rituximab) 4, 2

Initiate ultrasound screening every 6 months immediately for all high-risk patients, including Asian men >40 years or Asian women >50 years, any patient with cirrhosis, and patients with age >40 years with persistent ALT elevation 2
Continue HCC surveillance indefinitely, even if HBV DNA becomes undetectable on treatment 2

Monitor HBV DNA every 3 months until undetectable, then every 6 months 2, 3
Check ALT/AST every 3-6 months 2, 3
Annual quantitative HBsAg testing to assess for potential functional cure (HBsAg loss) 2, 3

Vaccinate against hepatitis A if anti-HAV negative as coinfection increases mortality 5.6- to 29-fold 2
Counsel on complete alcohol abstinence as even limited consumption worsens outcomes 2

Avoid treating based solely on HBV DNA or ALT in isolation - both parameters must be considered together with disease phase and fibrosis stage 1, 2